AXSM Axsome Therapeutics, Inc.

135.68USD+1.25%Mkt Cap: 7.14B USDP/E: —

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap7.14B USD
Enterprise Value6.96B USD
Revenue (TTM)865.27M USD
Gross Profit591.02M USD
Net Income (TTM)-183.17M USD
Revenue/Share16.79 USD
Last Price135.68 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)37.20
PEG—
EV/EBITDA-45.54
EV/Revenue8.04
P/S8.25
P/B67.67
EPS (TTM)-3.03 USD
EPS (Forward)3.65 USD
52W Range
123.009% of range260.19
52W High260.19 USD
52W Low123.00 USD
Profitability
Gross Margin92.56%
Oper. Margin-18.88%
EBITDA Margin-17.66%
Profit Margin-28.69%
ROE-207.46%
ROA-26.55%
ROIC—
ROCE-54.42%
Growth
Revenue Growth51.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-93.41M USD
CapEx (TTM)480.00K USD
FCF Margin-2.82%
FCF Yield-0.34%
Net Debt-89.63M USD
Net Debt/EBITDA0.59
Net Debt/FCF—
Balance Sheet
Debt/Equity2.47
Current Ratio1.42
Quick Ratio1.29
Book Value/Sh2.00 USD
Cash/Share5.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)264.62 USD
Upside (mean)+95.0%
Target Range220.00 USD – 315.00 USD
220.00+95.0% to mean315.00
# Analysts21
Ownership
Shares Out.52.60M
Float44.68M
Insiders15.02%
Institutions77.71%
Short Interest
Short Ratio3.3d
Short % Float9.60%
Short % Out.6.20%
Shares Short3.26M
Short (prev mo.)3.31M
Technical
SMA 50170.05 (-20.2%)
SMA 200196.81 (-31.1%)
Beta0.83
S&P 52W Chg12.08%
Avg Vol (30d)1.02M
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)37.4
MACD-7.6358
MACD Signal-9.0603
MACD Hist.+1.4246
BB Upper149.76 USD
BB Middle139.52 USD
BB Lower129.28 USD
BB Width14.68%
ATR (14)6.924 USD
Vol Ratio (20d)0.57x

About Axsome Therapeutics (NASDAQ: AXSM)

›

Axsome Therapeutics (NASDAQ: AXSM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,390 employees.

The shares were at 135.68 USD on 19 November 2026, down 2.7% over 52 weeks. Its 52-week range is 123.00 USD to 260.19 USD: the price is 47.9% below the high and 10.3% above the low.

Its market capitalisation is 7.14B USD.

Axsome Therapeutics reports return on equity of -207.5%, an operating margin of -18.9% and revenue up 51.9% year over year.

It holds more cash than debt, a net cash position of 89.63M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 264.62 USD is 95.0% above the current price. The next earnings report is expected on 22 February 2027.